Opus Genetics (NASDAQ:IRD) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Opus Genetics (NASDAQ:IRD) from a strong sell rating to a hold rating in a research report report published on Tuesday,Zacks.com reports.

Other analysts have also recently issued research reports about the company. Leerink Partners assumed coverage on Opus Genetics in a research report on Thursday, May 21st. They set an “outperform” rating and a $10.00 target price for the company. Chardan Capital reissued a “buy” rating and issued a $13.00 price target on shares of Opus Genetics in a report on Monday, July 6th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Opus Genetics in a report on Wednesday, June 17th. Guggenheim began coverage on Opus Genetics in a research note on Thursday, June 4th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Citigroup initiated coverage on shares of Opus Genetics in a report on Tuesday, April 28th. They set an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.69.

Opus Genetics Stock Performance

Shares of Opus Genetics stock opened at $3.76 on Tuesday. The company has a market capitalization of $310.76 million, a P/E ratio of -2.79 and a beta of 0.59. The company has a fifty day moving average of $3.79 and a 200 day moving average of $4.15. Opus Genetics has a fifty-two week low of $1.04 and a fifty-two week high of $5.81.

Opus Genetics (NASDAQ:IRD) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%.The business had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $2.63 million. Analysts forecast that Opus Genetics will post -1.05 EPS for the current year.

Insider Activity

In other news, Director Fighting Blindness Foundation sold 1,700,000 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $4.35, for a total transaction of $7,395,000.00. Following the sale, the director directly owned 3,792,171 shares of the company’s stock, valued at $16,495,943.85. This represents a 30.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO George Magrath sold 9,475 shares of the stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total value of $27,951.25. Following the transaction, the chief executive officer owned 1,731,869 shares of the company’s stock, valued at $5,109,013.55. This represents a 0.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,729,331 shares of company stock worth $7,481,629 over the last ninety days. Insiders own 11.70% of the company’s stock.

Hedge Funds Weigh In On Opus Genetics

Several institutional investors have recently bought and sold shares of IRD. Occudo Quantitative Strategies LP bought a new stake in shares of Opus Genetics in the 4th quarter worth about $25,000. Stoneridge Investment Partners LLC bought a new position in shares of Opus Genetics in the 2nd quarter valued at about $47,000. State of Wyoming purchased a new position in Opus Genetics in the second quarter worth about $65,000. Virtu Financial LLC purchased a new position in Opus Genetics in the fourth quarter worth about $34,000. Finally, Johnson Investment Counsel Inc. purchased a new position in Opus Genetics in the fourth quarter worth about $40,000. Institutional investors own 14.97% of the company’s stock.

Key Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Analysts raised earnings estimates: Brookline Capital Markets lifted its projections for Q3 2026 EPS to $(0.15) from $(0.18), FY2026 EPS to $(0.87) from $(1.31), FY2027 EPS to $(0.56) from $(0.77), and FY2028 EPS to $(0.61) from $(0.68). These revisions indicate expectations for narrower losses. Opus Genetics analyst estimates
• Positive Sentiment: HC Wainwright remains bullish: The firm raised its Q4 2026 EPS forecast to $(0.09) from $(0.14), increased its FY2026 estimate to $(1.03) from $(1.18), and raised FY2027 expectations to $(0.40) from $(0.46). It maintains a Buy rating and an $8 price target, well above the stock’s recent trading level.
• Positive Sentiment: Long-term profitability is projected: HC Wainwright forecasts positive EPS of $0.05 in FY2029 and $0.27 in FY2030, while Brookline projects $0.62 in FY2030. These estimates support a potential long-term recovery if Opus successfully advances its pipeline and controls spending.
• Neutral Sentiment: Short-interest data provides little signal: Reported short interest was zero shares with a zero-day days-to-cover ratio, suggesting the data is incomplete or unreliable rather than indicating meaningful investor positioning.
• Negative Sentiment: Losses remain substantial: Analysts still expect Opus Genetics to post a full-year loss of approximately $(1.05) to $(1.09) per share. The latest quarter also showed very low revenue of $0.76 million versus a $2.63 million consensus estimate, despite a modest EPS beat.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.